Scarica l'app Stockscreener
20.48
3.12%
-0.66
Precedente Chiudi:
$21.14
Aprire:
$21.04
Volume 24 ore:
1.45M
Relative Volume:
0.88
Capitalizzazione di mercato:
$1.78B
Reddito:
$139.71M
Utile/perdita netta:
$-209.36M
Rapporto P/E:
-6.9189
EPS:
-2.96
Flusso di cassa netto:
$-160.60M
1 W Prestazione:
-2.52%
1M Prestazione:
+0.05%
6M Prestazione:
+52.27%
1 anno Prestazione:
+35.81%
Intervallo 1D:
$20.43
$21.39
Intervallo di 1 settimana:
$20.43
$22.00
Portata 52W:
$8.58
$22.73
Syndax Pharmaceuticals Inc Stock (SNDX) Company Profile
Nome
Syndax Pharmaceuticals Inc
Settore
Industria
Telefono
781-419-1400
Indirizzo
730 THIRD AVENUE, NEW YORK, MA
Compare SNDX vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SNDX
Syndax Pharmaceuticals Inc
|
20.48 | 1.84B | 139.71M | -209.36M | -160.60M | -2.96 |
|
VRTX
Vertex Pharmaceuticals Inc
|
491.47 | 117.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
803.17 | 82.85B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
821.96 | 51.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.40 | 40.75B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.07 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
Syndax Pharmaceuticals Inc Stock (SNDX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-16 | Ripresa | H.C. Wainwright | Buy |
| 2025-09-10 | Ripresa | Stifel | Buy |
| 2025-09-04 | Ripresa | Guggenheim | Buy |
| 2025-08-05 | Reiterato | BTIG Research | Buy |
| 2025-07-10 | Iniziato | Goldman | Buy |
| 2024-10-24 | Iniziato | UBS | Buy |
| 2024-06-28 | Iniziato | Jefferies | Buy |
| 2024-01-31 | Downgrade | Scotiabank | Sector Outperform → Sector Perform |
| 2023-12-22 | Iniziato | Mizuho | Buy |
| 2023-10-25 | Iniziato | BofA Securities | Buy |
| 2023-10-11 | Iniziato | Goldman | Buy |
| 2023-07-27 | Iniziato | Scotiabank | Sector Outperform |
| 2023-07-11 | Iniziato | Guggenheim | Buy |
| 2023-04-17 | Ripresa | BTIG Research | Buy |
| 2023-01-31 | Iniziato | Stifel | Buy |
| 2023-01-03 | Iniziato | JP Morgan | Overweight |
| 2022-07-28 | Ripresa | B. Riley Securities | Buy |
| 2022-04-11 | Iniziato | H.C. Wainwright | Buy |
| 2022-02-15 | Iniziato | Goldman | Buy |
| 2021-06-04 | Ripresa | Robert W. Baird | Outperform |
| 2021-05-25 | Iniziato | Citigroup | Buy |
| 2021-02-18 | Iniziato | B. Riley Securities | Buy |
| 2020-12-03 | Iniziato | Stifel | Buy |
| 2020-05-22 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-05-22 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2020-05-18 | Downgrade | Citigroup | Buy → Neutral |
| 2020-05-11 | Reiterato | H.C. Wainwright | Buy |
| 2020-03-04 | Iniziato | Barclays | Overweight |
| 2020-01-13 | Reiterato | H.C. Wainwright | Buy |
| 2019-03-08 | Reiterato | H.C. Wainwright | Buy |
| 2019-01-04 | Iniziato | Robert W. Baird | Outperform |
| 2018-01-05 | Iniziato | B. Riley FBR, Inc. | Buy |
| 2017-03-16 | Iniziato | FBR & Co. | Outperform |
| 2017-03-02 | Iniziato | Instinet | Buy |
| 2016-10-07 | Iniziato | Guggenheim | Buy |
| 2016-03-28 | Iniziato | Citigroup | Buy |
| 2016-03-28 | Iniziato | JMP Securities | Mkt Outperform |
| 2016-03-28 | Iniziato | Morgan Stanley | Overweight |
Mostra tutto
Syndax Pharmaceuticals Inc Borsa (SNDX) Ultime notizie
BofA Raised Syndax (SNDX) PT to $28, Cites Heavy Pre-Announcements Lowering Earnings Impact - Insider Monkey
11 Most Promising Low-Cost Stocks to Buy Now - Insider Monkey
Have Insiders Sold Syndax Pharmaceuticals Shares Recently? - simplywall.st
SNDX: Robust product growth, expanding indications, and disciplined spending set up a path to profitability - TradingView
Is Syndax Pharmaceuticals Inc. still a buy after recent gains2025 Major Catalysts & Precise Buy Zone Identification - mfd.ru
Syndax Pharmaceuticals' Early Launch Success Signals Continued Growth Into 2026 (NASDAQ:SNDX) - Seeking Alpha
Insider Selling: Syndax Pharmaceuticals (NASDAQ:SNDX) CEO Sells 17,159 Shares of Stock - MarketBeat
Keith Goldan Sells 3,410 Shares of Syndax Pharmaceuticals (NASDAQ:SNDX) Stock - MarketBeat
Syndax Pharmaceuticals CEO Metzger sells $360k in stock By Investing.com - Investing.com Canada
Candriam S.C.A. Raises Holdings in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
Is Syndax Pharmaceuticals Inc. stock attractive for income investorsQuarterly Portfolio Report & Free Technical Confirmation Trade Alerts - mfd.ru
Setup Watch: Will Syndax Pharmaceuticals Inc benefit from green energy policiesMarket Trend Report & High Accuracy Trade Alerts - baoquankhu1.vn
Syndax Pharmaceuticals (NASDAQ:SNDX) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Michael Metzger Sells 7,412 Shares of Syndax Pharmaceuticals (NASDAQ:SNDX) Stock - MarketBeat
Insider Selling: Syndax Pharmaceuticals (NASDAQ:SNDX) CFO Sells 2,082 Shares of Stock - MarketBeat
Syndax Pharmaceuticals CEO sells $152,835 in SNDX stock By Investing.com - Investing.com Canada
Syndax Pharmaceuticals CEO sells $152,835 in SNDX stock - Investing.com
Syndax Announces Participation at the 2026 Guggenheim Emerging Outlook: Biotech Summit - The Manila Times
(SNDX) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - marketscreener.com
BofA Securities Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating, Raises Target Price to $28 - 富途牛牛
Keybank National Association OH Makes New $2.31 Million Investment in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Y Intercept Hong Kong Ltd Cuts Stock Position in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
Is Syndax Pharmaceuticals Inc. stock showing strong momentumWeekly Trend Summary & Reliable Entry Point Alerts - mfd.ru
Syndax’s Revumenib Solid-Tumor Trial Completion: What Investors Should Watch Next - TipRanks
Why is Syndax Pharmaceuticals Inc. stock going downPortfolio Update Summary & High Accuracy Trade Signal Alerts - mfd.ru
6 Analysts Assess Syndax Pharmaceuticals: What You Need To Know - Benzinga
Mizuho Forecasts Strong Price Appreciation for Syndax Pharmaceuticals (NASDAQ:SNDX) Stock - MarketBeat
SNDX: Mizuho Raises Price Target to $600 and Maintains 'Outperform' | SNDX Stock News - GuruFocus
Syndax Pharmaceuticals (NASDAQ:SNDX) Shares Up 9.5%What's Next? - MarketBeat
Barclays Raises Syndax (SNDX) PT to $35 on Positive Management Update, Model Rerating - MSN
Sector Gamma AS Acquires New Shares in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
Syndax’s Move to Commercial Stage With Two First-in-Class Drugs Might Change The Case For Investing In SNDX - Sahm
How (SNDX) Movements Inform Risk Allocation Models - Stock Traders Daily
Aug Summary: Is Syndax Pharmaceuticals Inc stock showing strong momentumJuly 2025 Trends & Capital Efficiency Focused Strategies - baoquankhu1.vn
Assessing Syndax Pharmaceuticals (SNDX) Valuation After Revuforj And Niktimvo Commercial Launch - Sahm
Several Syndax Pharmaceuticals Insiders Sell Shares Sending Potential Negative Signal - 富途牛牛
Aug Momentum: Is Syndax Pharmaceuticals Inc a defensive stockTreasury Yields & Weekly Return Optimization Plans - baoquankhu1.vn
Syndax Pharmaceuticals (NASDAQ:SNDX) Share Price Crosses Below Fifty Day Moving AverageHere's What Happened - MarketBeat
Syndax Pharmaceuticals, Inc. (SNDX): A Bull Case Theory - Finviz
Expanded Global Access To Revuforj Could Be A Game Changer For Syndax Pharmaceuticals (SNDX) - Sahm
First Week of March 20th Options Trading For Syndax Pharmaceuticals (SNDX) - Nasdaq
Is It Time To Reassess Syndax Pharmaceuticals (SNDX) After Last Year’s 62.5% Share Price Gain? - Yahoo Finance
Trading Systems Reacting to (SNDX) Volatility - Stock Traders Daily
Rate Hike: Will Syndax Pharmaceuticals Inc benefit from green energy policiesWeekly Profit Report & Free Expert Approved Momentum Trade Ideas - baoquankhu1.vn
Insider Buy: Will Syndax Pharmaceuticals Inc stock recover faster than peersJuly 2025 PreEarnings & AI Driven Stock Reports - Bộ Nội Vụ
Assessing Syndax Pharmaceuticals (SNDX) Valuation After Expanded Revuforj Access And Recent Leukemia Progress - Sahm
Syndax Reports Preliminary 2025 Financial Highlights and Provides Business Updates at the 44th Annual J.P. Morgan Healthcare Conference - Sahm
Market Trends: Can Syndax Pharmaceuticals Inc disrupt its industryPortfolio Return Summary & Risk Controlled Stock Alerts - baoquankhu1.vn
New cancer drugs see rising demand as drugmaker shares 2025 sales - Stock Titan
Syndax Pharmaceuticals Inc Azioni (SNDX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.12%
0.87%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):